CTI BioPharma Corp.

12/02/2021 | Press release | Distributed by Public on 12/02/2021 15:37

CTI BioPharma to Present at the JMP Securities Hematology & Oncology Summit on Monday, December 6

SEATTLE, Dec. 2, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the JMP Securities Hematology & Oncology Summit at 3:40 p.m. ET. The conference will be held in a virtual meeting format.

Presentation details:
Event: JMP Securities Hematology & Oncology Summit
Date: Monday, December 6, 2021
Time: 3:40 p.m. ET

The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.

About CTI BioPharma Corp.
We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on developing and commercializing pacritinib, our product candidate currently in active late-stage development. We are headquartered in Seattle, Washington.

CTI BioPharma Investor Contacts:
Argot Partners
+212-600-1902
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-jmp-securities-hematology--oncology-summit-on-monday-december-6-301436710.html

SOURCE CTI BioPharma Corp.